Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

• Status: Completed
• Trial end date: 2019-11-27
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanda Pharmaceuticals
• Treatments: Iloperidone

Criteria

Inclusion Criteria:

• Male or female patients 18 to 65 years of age (inclusive)

• Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type as per DSM-V criteria

• Symptomatically stable within the past two months

Exclusion Criteria:

• Exposure to any investigational medication, including placebo, in the past 60 days

• Non-response to clozapine